<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3383">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556149</url>
  </required_header>
  <id_info>
    <org_study_id>00110011</org_study_id>
    <nct_id>NCT04556149</nct_id>
  </id_info>
  <brief_title>imPulse™ Una Full-spectrum, Over Clothing E-stethoscope</brief_title>
  <official_title>SARS-CoV-2/COVID-19 Pilot Study of the Audible and Inaudible Vibroacoustic E-stethoscope - imPulse™ Una</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Level 42 AI, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Level 42 AI, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study generates robust clinical data to train ML/AI algorithms of the Sponsor's imPulse™
      Una full-spectrum e-stethoscope for digital diagnostic feature synthesis of symptomatic
      SARS-CoV-2/COVID-19 biosignatures for rapid and accurate mass screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study is designed to evaluate the ability of the imPulse™ Una e-stethoscope to
      differentiate vibroacoustic signals in inpatients with and without confirmed COVID-19 as the
      first step to establish the performance characteristics - sensitivity, specificity, positive
      and negative predictive value - of the imPulse™ Una device for early and rapid, point-of-care
      diagnosis of COVID-19. This will inform the utility and design of further larger-scale
      studies using the device.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance characteristics</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
    <description>Sensitivity, specificity, positive and negative predictive values - of the imPulse™ Una device for point-of-care diagnosis of COVID-19.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>Coronavirus</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>Inpatients with confirmed COVID-19 with pulmonary symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Control</arm_group_label>
    <description>Inpatients without COVID-19 with non-pulmonary diagnoses or symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>imPulse™ Una e-stethoscope</intervention_name>
    <description>The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Matched Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Philips Lumify Ultrasound System</intervention_name>
    <description>Point-of-care ultrasound</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Matched Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult men and women will be recruited from among hospitalized patients with symptomatic
        COVID-19 infection who are not receiving ventilator support. One hospitalized control
        without lung disease or pulmonary symptoms will be selected for each case.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Individuals hospitalized within a Johns Hopkins-affiliated hospital

          -  Able to understand and willingness to comply with study procedures

          -  Cases - inpatients with positive COVID-19 PCR test, collected from a respiratory
             sample within the last 7 days, AND pulmonary symptoms within 72 hours of enrollment

          -  Controls - inpatients without COVID-19 diagnosis and no pulmonary diagnosis or
             symptoms

          -  Cases or Control not able to sit or stand will be allowed to participate in just the
             parts of the staircase exam they're capable of doing.

        Exclusion Criteria

          -  Assisted ventilation, including high flow nasal cannula, or ventilator support

          -  Unable to comply with study procedures, defined at investigator's discretion

          -  Participants with any visible skin infections or open wounds in areas where the
             imPulse™ Una device would be applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Dooley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ed Fuchs, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fuchs, MBA</last_name>
    <phone>(410) 614-8762</phone>
    <email>ejfuchs@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jumbe, PhD</last_name>
    <phone>(650) 515-6112</phone>
    <email>shasha@level42.ai</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-5554</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ed Fuchs, MBA</last_name>
      <phone>410-614-8762</phone>
      <email>ejfuchs@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Dooley, MD, PhD</last_name>
      <phone>(410) 499-2307</phone>
      <email>kdooley1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infrasound</keyword>
  <keyword>e-stethoscope</keyword>
  <keyword>biosignature</keyword>
  <keyword>SARS-CoV-2/COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

